AMAL
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva.
AMAL has raised €29M across 1 funding round from 1 investor, most recently a Series B round in Nov 2018. Based in Geneva, Switzerland; founded 2012; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€29M
€28,911,863
Funding rounds
1
Investors
1
distinct backers
Active since
2018-11
latest 2018-11
Funding by year
EUR raised per yearAMAL — funding by year — interactive chart.
Data table
| AMAL — funding by year | |
|---|---|
| 2018 | €29M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-11-12 | Series B | €29M | Boehringer Ingelheim Venture Fund | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData